AstraZeneca Annual Report and Form 20-F Information 2011

24 Employee costs and share plans for employees continuedUSIn the US, there are two all-employee short-term or annual performance bonus plans in operation to differentiate and reward strong individualperformance. Annual bonuses are paid in cash. There is also one senior staff long-term incentive scheme, under which approximately 70participants may be eligible for awards granted as AstraZeneca ADSs. AstraZeneca ADSs necessary to satisfy the awards are purchased in themarket or funded via a share trust. The AstraZeneca Performance Share Plan and the AstraZeneca Global Restricted Stock Plan operate inrespect of relevant employees in the US.Share plansThe charge for share-based payments in respect of share plans is $153m (2010: $120m; 2009: $81m). The plans are equity settled.The AstraZeneca Performance Share PlanThis plan was approved by shareholders in 2005 for a period of 10 years. Generally, awards can be granted at any time, but not during a closeperiod of the Company. The first grant of awards was made in June 2005. The main grant of awards in 2011 under the plan was in March, witha further smaller grant in August. Awards granted under the plan vest after three years and can be subject to the achievement of performanceconditions. For awards to all participants in 2011, except employees of MedImmune, 50% of the award will vest subject to the performance of theCompany’s total shareholder return (TSR) compared with that of a selected peer group of other pharmaceutical companies, and 50% will vestsubject to the achievement of a net cash flow target. A separate performance condition applies to employees of MedImmune. The RemunerationCommittee has responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated,including agreeing performance targets and which employees should be invited to participate. A fuller description of this plan can be found inthe AstraZeneca Performance Share Plan section from page 120 in the Directors’ Remuneration Report.Shares awarded in March 2009 1,190 1140 16.70Shares awarded in August 2009 8 1424 23.18Shares awarded in March 2010 2,002 1495 22.38Shares awarded in May 2010 436 1431 21.48Shares awarded in August 2010 139 1614 24.95Shares awarded in November 2010 4 N/A 25.11Shares awarded in March 2011 2,964 1427 23.09Shares awarded in August 2011 127 1421 23.33Shares’000WAFV 1penceWAFV 1$1Weighted average fair value.The AstraZeneca Investment PlanThis plan was introduced in 2010 and approved by shareholders at the 2010 AGM. The main grant of awards in 2011 under the plan was in March,with a further smaller grant in August. Awards granted under the plan vest after eight years and are subject to performance conditions measuredover a period of between three and eight years. For awards granted in 2011, the performance conditions relate to the annual dividend paid toshareholders and dividend cover over a four-year performance period. The awards are then subject to a four-year holding period before theycan vest. The Remuneration Committee has responsibility for agreeing any awards under the plan and for setting the policy for the way in whichthe plan should be operated, including agreeing performance targets and which employees should be invited to participate. A fuller descriptionof this plan can be found in the AstraZeneca Investment Plan section from page 120 of the Directors’ Remuneration Report.Shares awarded in May 2010 76 2575 38.66Shares awarded in August 2010 15 2904 N/AShares awarded in March 2011 95 2853 46.18Shares awarded in August 2011 3 2841 N/AShares’000WAFVpenceWAFV$The AstraZeneca Global Restricted Stock PlanThis plan was introduced in 2010 and replaces the AstraZeneca Pharmaceuticals LP Restricted Stock Unit Award Plan and the MedImmune,Inc. 2008 Restricted Stock Unit Award Plan described below. The main grant of awards in 2011 under the plan was in March, with a furthersmaller grant in August. This plan provides for the grant of restricted stock unit (RSU) awards to selected below SET-level employees and isused in conjunction with the AstraZeneca Performance Share Plan to provide a mix of RSUs and performance shares. Awards typically veston the third anniversary of the date of grant and are contingent on continued employment with the Company. The Remuneration Committeehas responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated.Shares awarded in March 2010 2,672 2989 44.75Shares awarded in August 2010 8 3227 49.89Shares awarded in March 2011 2,706 2853 46.18Shares awarded in August 2011 54 2841 46.65Shares’000WAFVpenceWAFV$Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011 Financial Statements 177